Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey

 

escrs app advert

Posters

Search Title by author or title

Clinical outcomes of central circular descemetorhexis in patients with Fuchs' endothelial corneal dystrophy

Poster Details

First Author: E.Malyutina RUSSIA

Co Author(s):    B. Malyugin   O. Antonova   A. Belodedova   A. Galyastanov           

Abstract Details

Purpose:

To evaluate the long-term clinical outcomes of circular descemetorhexis without transplantation in patients with Fuchs' endothelial corneal dystrophy

Setting:

S. Fyodorov Eye Microsurgery Federal Institution, Moscow, Russia

Methods:

The group included 24 eyes of 23 patients (17 women 6 man) with the mean age of 65,61± 10,17 years (range 51-84) having FECD and cataract, underwent US phacoemulsification, in-the-bag hydrophobic acrylic IOL implantation followed by CDR (4,0 mm in diameter) without endothelial transplantation. Best-corrected visual acuity (BCVA), corneal pachymetry, endothelial cell density (ECD), was evaluated preoperatively, 1 day and 1, 3, 6, 9 months postoperatively

Results:

DMEK performed in 7 eyes within 8 months of the procedure. Mean preoperative BCVA was 0,32±0,16. Further BCVA was 0,07±0,05 on the 1st day;0,38±0,26 in 1 month; 0,68±0,21 in 3 months; 0,74±0,19 in 6 months; 0,68±0,24 in 9 months. Corneal pachymetry was 531,59±193,53; 770,12±277,89; 604,85±234,55; 550,22±205,63; 530,22±198,26; 585,92±198,26. Corneal clearance was achieved in 17 cases reaching 8-month. ECD in 3-months were 627,67±227,19; in 6 months 646,93±193,49; in 9 months 602,82±157,57 cells/mm2.

Conclusions:

DR without endothelial replacement is successful in 70,8 % of cases. CDR is a viable option for visual rehabilitation in selected patients with Fuchs' corneal endothelial dystrophy and cataract, eliminating the need for endothelial grafting. Further research is necessary to find out which category of patients will benefit best from that technology

Financial Disclosure:

None

Back to Poster listing